Overview
Nanotope is a regenerative medicine company that leverages a platform technology to address multiple therapeutic markets. It is developing a suite of products, each customized to regenerate specific tissues: including neuronal, vascular, cartilage, bone, and myocardial. Products are peptide-based, injectable compounds that work with surviving cells in and around the point of injury to initiate and support regeneration. Once regeneration is complete, the compounds are safely broken down and removed by the body. Nanotope's lead candidates, shown to be effective in multiple animal models, target:
- spinal cord regeneration for the reversal of paralysis
- cartilage regeneration
- advanced wound healing
Nanotope's Platform Technology
Nanotope's platform consists of a proprietary class of molecules that self assemble into a matrix of nanofibers capable of actively directing surviving cells to re-grow damaged tissue. The customizable matrix, or gel, of nanofibers is a three-dimensional bioactive, or "smart", scaffolding in which cells and tissues may grow and differentiate.
Two primary features of the gel are both critical and unique: the controlled transition from a liquid to solid, and customizable bioactivity. The former allows for the injection of a liquid that becomes a solid scaffold in situ upon exposure to physiological conditions. The latter allows Nanotope to program the gel to direct specific cell and tissue development in a virtually limitless way. It is this factor that allows Nanotope to use the same core proprietary technology for regeneration of different tissues and optimize regeneration within a single tissue.
News
08/17/2011
Imagine splitting a human hair 100,000 times. Each split is a single nanometer in diameter, the size of a nanostructure.
More01/12/2011
Making paralyzed mice walk was just the first step for Samuel Stupp. Now he and his team are on a mission to help our bodies repair themselves.
More10/18/2010
Nanotope, Inc., has entered into an agreement with Smith & Nephew, Inc., a member of the Smith & Nephew plc group (LSE: SN; NYSE: SNN) to develop a cartilage regeneration product for human healthcare markets using a subset of its proprietary regenerative medicine technology.
More